|
WO2011016811A1
|
|
Methods for reducing the incidence of chemotherapy - induced mucositis
|
|
WO2007146823A2
|
|
Carbohydrate derivatives of heptanoic acids
|
|
WO2008011216A2
|
|
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
|
|
WO2006017417A2
|
|
Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
|
|
US2005282773A1
|
|
Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
|
|
WO2006002106A2
|
|
Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
|
|
EP1735012A2
|
|
Targeting of radioimagining and radiotherapy agents
|
|
US2005239743A1
|
|
Compositions and methods to inhibit restenosis
|
|
EP1734819A1
|
|
Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
|
|
EP1718146A2
|
|
Compositions and methods used to treat acne and candida
|
|
AU2004272022A1
|
|
Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
|
EP1643969A2
|
|
Compositions and methods for hydrophobic drug delivery
|
|
US2004038935A1
|
|
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
|
WO02076474A1
|
|
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
|
AU9299301A
|
|
Methods and compositions for reducing side effects in chemotherapeutic treatments
|
|
US6645946B1
|
|
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
